WHAT YOU NEED TO KNOW What The Next U.S. Patent and Trademark Office (USPTO) Director Could Mean For Drug Prices: As anticipation builds around who the next USPTO director will be, the Coalition Against Patent Abuse (CAPA) is highlighting the importance of making the right choice to tackle anti-competitive behavior that will help lower drug prices.  […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System.  Part IV: IPR & Heart Disease – Knocking Down Erroneously Extended Patents. Read the full story below: In 2017, the patent for an anti-clotting drug prasugrel, under […]

Continue Reading

Today, some major pharmaceutical companies continue to game the U.S. patent system by limiting generic competition while keeping drug prices high for millions of patients.  Big Pharma’s manipulation of patent laws prevent or delay generic medications from going to market which ultimately denies patients access to more affordable, life-saving, and quality of life enhancing drugs.  […]

Continue Reading